Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0149521 (chronic pancreatitis)
 7,199 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The incidence of the point mutation of K-ras oncogene at codon 12 in surgical or autopsy specimens of pancreatic carcinoma (PC) is reportedly extremely high ranging from 75 to over 90%, and the K-ras mutation found in PC is almost exclusively present in codon 12. The GGT to GAT transition of the 12th codon is observed in more than 50% of PC of Japanese patients, although the incidences of transition of GGT to CGT, GTT, and GAT are essentially equal in PC of European countries. With this point in mind, the authors attempted to detect K-ras mutations in DNA obtained from pancreatic juice (PJ) collected endoscopically. K-ras mutations at codon 12 were found in 55% of 20 PC patients by PCR and ASO probe hybridization method, and in 80% of 25 PC patients by PCR-RFLP method. On the other hand, K-ras mutations were negative in PJ from chronic pancreatitis with one exception by PCR-RFLP method. Other authors also reported almost the same results. These results suggest that analysis of K-ras oncogene in PJ can be useful for qualitative diagnosis of PC, and would be expected as a novel tool for early detection of PC.
 ...
PMID:[Mutation of the K-ras oncogene in pancreatic carcinoma, and application of its detection in pancreatic juice to diagnose pancreatic carcinoma]. 769 81

Point mutations in K-ras codon 12 were detected in 7 of 10 specimens (70%) of frozen tissues. To determine when point mutations appear in the oncogenic stage, paraffin-embedded tissues of pancreatic cancer, hyperplastic ductal lesions in pancreatic cancer and in chronic pancreatitis were used. DNA extracted from the paraffin-embedded tissues classified as cancer, atypical and nonatypical hyperplasia of the pancreatic duct epithelium, and normal tissue from pancreatic cancer patients and those classified as atypical hyperplasia of the pancreatic duct epithelium and normal tissue from chronic pancreatitis patients were amplified by the polymerase chain reaction (PCR) method. Point mutations were detected in 8 of 17 cancer cases (47.0%). In 5 of 8 point mutation positive cases, atypical hyperplasias were found in the surrounding tissues. In all 5 of these atypical hyperplasia, point mutations, that is, GGT-GTT (Gly-Val) and GGT-GAT (Gly-Asp), were detected. The same transitions were observed in the cancer of these 5 cases. These results suggest a strong relationship between cancer and atypical hyperplasia surrounding cancer. Although atypical hyperplasia around cancer was histologically very similar to that found in chronic pancreatitis, all 5 atypical and 5 nonatypical hyperplasias in chronic pancreatitis were negative for ras point mutation. Thus, the result argues against an association between chronic pancreatitis and pancreatic cancer.
 ...
PMID:The role of Ras mutation in pancreatic cancer, precancerous lesions, and chronic pancreatitis. 811 25

KRAS2 gene mutations are found in 75-90% of infiltrating pancreatic ductal adenocarcinomas but can also be present with other nonneoplastic pancreatic diseases. We recently developed a novel sensitive assay for point mutation detection, called "LigAmp", which can detect one mutant molecule in the presence of 10,000 wild-type molecules and can quantify mutant DNA over a wide dynamic range. We analyzed KRAS2 mutations in surgically-collected pancreatic duct juice samples from patients with pancreatic adenocarcinoma (n = 27) and chronic pancreatitis(n = 9). DNA sequencing demonstrated that 17 of the 27 pancreatic cancers harbored KRAS2 mutations at codon 12, including G12D (GGT-->GAT), G12V (GTT), and G12R (CGT). We determined the relative amounts of each KRAS2 mutant by simultaneously quantifying wild-type and mutant KRAS2 DNA. For all pancreatic adenocarcinoma patients, the dominant KRAS2 mutation detected in the pancreatic juice corresponded to that found in the primary cancer. Mutation levels were substantially higher in patients with pancreatic cancer (0.05 to 82% of total KRAS2 molecules) compared to those with chronic pancreatitis (0 to 0.7%). Among patients with mutant KRAS2 positive cancers, all but one (94%) had mutant KRAS2 DNA concentrations of more than 0.5% in their pancreatic juice samples, whereas only 1 of 9(11%) pancreatic juice samples from patients with chronic pancreatitis had more than 0.5% mutant KRAS2 DNA, corresponding to a sensitivity of 94% and a specificity of 89%. LigAmp quantification of mutant KRAS2 in pancreatic juice differentiates pancreatic adenocarcinoma from chronic pancreatitis, and may be a useful early detection tool for pancreatic cancer.
 ...
PMID:Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. 1861 59